Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

Missense mutations in the p53 tumor suppressor inactivate its antiproliferative properties but can also promote metastasis through a gain-of-function activity. We show that sustained expression of mutant p53 is required to maintain the prometastatic phenotype of a murine model of pancreatic cancer, a highly metastatic disease that frequently displays p53 mutations. Transcriptional profiling and functional screening identified the platelet-derived growth factor receptor b (PDGFRb) as both necessary and sufficient to mediate these effects. Mutant p53 induced PDGFRb through a cell-autonomous mechanism involving inhibition of a p73/NF-Y complex that represses PDGFRb expression in p53-deficient, noninvasive cells. Blocking PDGFRb signaling by RNA interference or by small molecule inhibitors prevented pancreatic cancer cell invasion in vitro and metastasis formation in vivo. Finally, high PDGFRb expression correlates with poor disease-free survival in pancreatic, colon, and ovarian cancer patients, implicating PDGFRb as a prognostic marker and possible target for attenuating metastasis in p53 mutant tumors.

[1]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[2]  Jochen Gaedcke,et al.  DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma , 2012, PloS one.

[3]  J. Richardson,et al.  The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. , 2003, Blood.

[4]  C. Verbeke,et al.  3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing , 2013, BMC Cancer.

[5]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[6]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[7]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[8]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[9]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[10]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[11]  C. Prives,et al.  A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. , 2009, Genes & Development.

[12]  H. Nakshatri,et al.  Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion , 2007, Oncogene.

[13]  W. B. Derry Faculty Opinions recommendation of A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. , 2009 .

[14]  U. Moll,et al.  Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis , 2013, Cell Death and Differentiation.

[15]  P. Dong,et al.  Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis , 2012, Oncogene.

[16]  A. Hinke,et al.  Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205 , 2013, British Journal of Cancer.

[17]  M. Hediger,et al.  Mammalian iron transporters: families SLC11 and SLC40. , 2013, Molecular aspects of medicine.

[18]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.

[19]  J. Pietenpol,et al.  Targeting mutant p53 in human tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Bracken,et al.  Mutant p53 drives invasion in breast tumors through up-regulation of miR-155 , 2013, Oncogene.

[21]  Tobias Sjöblom,et al.  PDGF receptors as cancer drug targets. , 2003, Cancer cell.

[22]  T. Borodina,et al.  Transcriptome analysis by strand-specific sequencing of complementary DNA , 2009, Nucleic acids research.

[23]  Patrick J. Paddison,et al.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo , 2003, Nature Genetics.

[24]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[25]  R. Mantovani,et al.  Conservation and divergence of NF-Y transcriptional activation function. , 1998, Nucleic acids research.

[26]  F. Holstege,et al.  PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. , 2013, Neoplasia.

[27]  Toshio Ohhashi,et al.  PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. , 2004, Cancer cell.

[28]  Shiyun Ling,et al.  TopBP1 Mediates Mutant p53 Gain of Function through NF-Y and p63/p73 , 2011, Molecular and Cellular Biology.

[29]  T. Yeatman,et al.  Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. , 2010, Gastroenterology.

[30]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[31]  K. Funa,et al.  Isolation and Characterization of the Mouse PDGF β-Receptor Promoter , 1995 .

[32]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[33]  C. Prives,et al.  Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? , 2007, Oncogene.

[34]  S. Offermanns,et al.  Gα12/13 Is Essential for Directed Cell Migration and Localized Rho-Dia1 Function* , 2005, Journal of Biological Chemistry.

[35]  P. Sismondi,et al.  Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma , 1995, Cancer.

[36]  Alexander E. Kel,et al.  TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..

[37]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[38]  J. Grosshans,et al.  Positive feedback between Dia1, LARG, and RhoA regulates cell morphology and invasion. , 2007, Genes & development.

[39]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[40]  K. Pierce,et al.  Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[42]  Antonio Rosato,et al.  A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.

[43]  H. Uramoto,et al.  p73 Independent of c-Myc Represses Transcription of Platelet-derived Growth Factor β-Receptor through Interaction with NF-Y* , 2002, The Journal of Biological Chemistry.

[44]  D. Kerr,et al.  The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Ishisaki,et al.  Nuclear factor Y controls the basal transcription activity of the mouse platelet-derived-growth-factor beta-receptor gene. , 1997, European journal of biochemistry.

[46]  G. Blandino,et al.  Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells , 2014, Oncogene.

[47]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[48]  A. Fersht,et al.  Structural biology of the tumor suppressor p53 and cancer-associated mutants. , 2007, Advances in cancer research.

[49]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[50]  Nadav S. Bar,et al.  Landscape of transcription in human cells , 2012, Nature.

[51]  C. Prives,et al.  A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain , 2001, Molecular and Cellular Biology.

[52]  A. Levine,et al.  Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.

[53]  Yujia Dai,et al.  Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature , 2010, Expert opinion on therapeutic patents.

[54]  I. Wistuba,et al.  TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs , 2010, Nature.

[55]  Christof Fellmann,et al.  Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi , 2011, Nature Biotechnology.

[56]  Giulia Piaggio,et al.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.

[57]  K. Funa,et al.  Isolation and characterization of the mouse PDGF beta-receptor promoter. , 1995, Biochemical and Biophysical Research Communications - BBRC.